Biotech Startups

Tenmile is an Australian health technology venture capital firm that funds and supports early-stage biotech and medtech innovations with the goal of bringing Australian research breakthroughs to global markets. Beyond capital, the firm provides portfolio companies with talent recruitment support, international partnerships, and regulatory guidance.

1 investor

Tensegrity Pharma develops early-stage clinical development programs and drug discovery services for the pharmaceutical industry. The company leverages a network of investigators, contract research organizations, and key opinion leaders to support new drug programs.

1 investor

Tensive is a clinical-stage medical device company developing REGENERA™/SOFTAG™ resorbable biopolymer scaffolds for natural breast reconstruction and tissue marking following lumpectomy. It serves breast cancer patients and surgeons, working in the advanced biomaterials and medical device field.

1 investor

Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine. The company focuses on biologic drug development and innovation in the therapeutic sector.

1 investor

Creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.

1 investor

Teora develops AI-driven, feed-based and foliar-spray biologics for farm health and growth, using bioinformatics and precision fermentation to prevent disease and boost yields without antibiotics, hormones, or cold-chain vaccines. Its SOLAQ platform is proven in aquaculture and aimed at scaling to livestock, poultry, companion animals, and agriculture.

1 investor

TerraVera develops technology and services supporting agricultural growers and beekeepers, with a focus on pollinator health and sustainable agriculture. The company positions its products around protecting ecosystems and improving outcomes for the farming and beekeeping community.

1 investor

Terrabiom works on soil restoration by reestablishing microbial communities (mycorrhizal fungi and bacteria) so that native vegetation can take root and self-sustaining forest ecosystems can regenerate. It focuses on reforestation and ecological restoration of degraded soils, including native species such as ñirre, notro, lenga, canelo, coigüe, alerce, and araucaria.

1 investor

Terragia develops consolidated bioprocessing technology using engineered thermophilic bacteria to convert cellulosic biomass, such as crop residues and perennial crops, into ethanol, other biofuels, and co-products at costs competitive with petroleum. Its technology targets low-carbon liquid fuels for hard-to-electrify transportation modes like aviation, marine, and long-haul trucking.

1 investor

Terrana Biosciences is an agricultural biotech company applying RNA technology to plant health, developing a platform that gives crops new traits such as drought tolerance and shorter ripening times. The company works on RNA-based solutions for agriculture and was built out of Flagship Pioneering's RNA expertise.

1 investor

Terumo Medical Corporation manufactures medical devices and healthcare products across four divisions, including interventional systems for vascular access, injection and infusion devices, drug delivery devices, and precision medicine software and care pathway consulting. It serves healthcare providers as a subsidiary of Terumo Corporation.

1 investor

Tesabio.ai is a platform that uses AI to identify small molecules capable of rebalancing dysregulated microRNA networks in complex diseases by optimizing for whole-network restoration rather than single-target approaches. The platform serves biotech and pharmaceutical companies developing novel therapeutics across disease indications.

1 investor

GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients. Its research focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

1 investor

TesoRx is a clinical-stage pharmaceutical company developing new therapies based on a proprietary drug delivery platform, focused on conditions with unmet needs and limited or sub-optimal treatment options.

1 investor

Tetra Pharm develops next-generation drugs targeting neurological disorders including chronic pain, Alzheimer's, and obesity. The company also provides contract development and manufacturing organization (CDMO) services encompassing drug delivery systems, GMP manufacturing, and consultancy to pharmaceutical clients.

1 investor

Tetra Therapeutics (Tetra Discovery Partners) was a discovery-based pharmaceutical company developing clinical programs including treatments for Fragile X Syndrome. It was acquired by Shionogi & Co. in 2020, and its former clinical trials and research programs are now managed by Shionogi Inc., a U.S. subsidiary.

1 investor

Tetratherix develops a biostealth fluid matrix built on its Tetramatrix platform technology to create regenerative medicine therapies, solutions, and products. The company operates in the regenerative medicine and medical device field and runs its own advanced manufacturing facility.

1 investor

1 investor

A biotech company developing novel biologics designed to target and eliminate the drivers of cancer recurrence and metastasis. It combines early-stage research with platform design to create treatments for resilient cancers.

1 investor

TG Therapeutics is a biopharmaceutical company focused on developing treatments for cancer patients. The company is committed to patient care and is guided by a board with extensive expertise in biotechnology, pharmaceutical development, financial management, and medical oncology.

1 investor

Thabor Therapeutics is an INSERM spin-off developing a first-in-class therapeutic antibody targeting AGR2 for treating inflammatory mucosal diseases. The company focuses on immunology and therapeutic antibody development.

1 investor

1 investor

The Blue Box is a diagnostic device that uses a urine reader with an electronic nose and AI analysis to detect breast cancer biomarkers in women aged 20-49 who lack reliable screening methods. The company has validated its technology through pilots with over 450 patients across 7 hospitals.

1 investor

The Century of Biology is a newsletter publishing analysis, data, and commentary about companies and ideas in the field of biology. It is written by Elliot Hershberg and distributed on Substack to over 28,000 subscribers.

1 investor